These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 30146790)

  • 41. An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors.
    Lamos EM; Hedrington M; Davis SN
    Expert Opin Drug Saf; 2019 Aug; 18(8):691-701. PubMed ID: 31150300
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of the administration of teneligliptin every day versus every other day in Japanese patients with type 2 diabetes: a randomized non-inferior test.
    Kamiko K; Aoki K; Kamiyama H; Taguri M; Shibata E; Ashiya Y; Minagawa F; Shinoda K; Nakajima S; Terauchi Y
    J Clin Pharmacol; 2015 Feb; 55(2):144-51. PubMed ID: 25159300
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combination therapy of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: rationale and evidences.
    Singh AK; Singh R
    Expert Rev Clin Pharmacol; 2016; 9(2):229-40. PubMed ID: 26589238
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Glycemic/metabolic responses to identical meal tolerance tests at breakfast, lunch and dinner in Japanese patients with type 2 diabetes mellitus treated with a dipeptidyl peptidase-4 inhibitor and the effects of adding a mitiglinide/voglibose fixed-dose combination.
    Ono Y; Kamoshima H; Nakamura A; Nomoto H
    Expert Opin Pharmacother; 2014 Sep; 15(13):1785-95. PubMed ID: 25046055
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis.
    Min SH; Yoon JH; Hahn S; Cho YM
    Diabetes Metab Res Rev; 2017 Jan; 33(1):. PubMed ID: 27155214
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of Additional Administration of a Selective Inhibitor of Sodium Glucose co-transporter-2 Inhibitor on the Glycemic Control in Japanese Type 2 Diabetes Mellitus Patients Receiving Treatment with a Dipeptidyl Peptidase-4 Inhibitor.
    Kusunoki M; Sato D; Sakazaki T; Miyata T; Tsutsumi K; Oshida Y
    Drug Res (Stuttg); 2020 Apr; 70(4):131-136. PubMed ID: 32164029
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ameliorating effect of the novel dipeptidyl peptidase-4 inhibitor teneligliptin on psoriasis: A report of two cases.
    Nagai H; Fujiwara S; Takahashi Y; Nishigori C
    J Dermatol; 2015 Nov; 42(11):1094-7. PubMed ID: 26031638
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Pharmacological and clinical profile of a novel DPP-4 inhibitor teneligliptin hydrobromide hydrate (TENELIA(®)].
    Goda M; Akahoshi F; Ishii S; Terata R; Hayashi Y
    Nihon Yakurigaku Zasshi; 2013 Sep; 142(3):134-43. PubMed ID: 24025495
    [No Abstract]   [Full Text] [Related]  

  • 49. Preventive effect of ipragliflozin on nocturnal hypoglycemia in patients with type 2 diabetes treated with basal-bolus insulin therapy: An open-label, single-center, parallel, randomized control study.
    Okajima F; Nagamine T; Nakamura Y; Hattori N; Sugihara H; Emoto N
    J Diabetes Investig; 2017 May; 8(3):341-345. PubMed ID: 27762088
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.
    Devineni D; Morrow L; Hompesch M; Skee D; Vandebosch A; Murphy J; Ways K; Schwartz S
    Diabetes Obes Metab; 2012 Jun; 14(6):539-45. PubMed ID: 22226086
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study.
    Patorno E; Goldfine AB; Schneeweiss S; Everett BM; Glynn RJ; Liu J; Kim SC
    BMJ; 2018 Feb; 360():k119. PubMed ID: 29437648
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Relationship of Eating Patterns and Metabolic Parameters, and Teneligliptin Treatment: Interim Results from Post-marketing Surveillance in Japanese Type 2 Diabetes Patients.
    Kadowaki T; Haneda M; Ito H; Sasaki K; Hiraide S; Matsukawa M; Ueno M
    Adv Ther; 2018 Jun; 35(6):817-831. PubMed ID: 29777520
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors.
    Wysham CH; Lefebvre P; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Chow W; Pfeifer M; Duh MS
    BMC Endocr Disord; 2017 Jun; 17(1):32. PubMed ID: 28595617
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Yoshida T; Akahoshi F; Sakashita H; Kitajima H; Nakamura M; Sonda S; Takeuchi M; Tanaka Y; Ueda N; Sekiguchi S; Ishige T; Shima K; Nabeno M; Abe Y; Anabuki J; Soejima A; Yoshida K; Takashina Y; Ishii S; Kiuchi S; Fukuda S; Tsutsumiuchi R; Kosaka K; Murozono T; Nakamaru Y; Utsumi H; Masutomi N; Kishida H; Miyaguchi I; Hayashi Y
    Bioorg Med Chem; 2012 Oct; 20(19):5705-19. PubMed ID: 22959556
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Concurrent Use of Teneligliptin and Canagliflozin Improves Glycemic Control with Beneficial Effects on Plasma Glucagon and Glucagon-Like Peptide-1: A Single-Arm Study.
    Noda T; Ebihara E; Ueno H; Sadohara K; Tanaka Y; Nagatomo Y; Murakami Y; Yonamine S; Tsuchimochi W; Sakoda H; Yamaguchi H; Nakazato M
    Diabetes Ther; 2019 Oct; 10(5):1835-1846. PubMed ID: 31300948
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors: Sequential or simultaneous start?
    Goncalves E; Bell DSH
    Diabetes Obes Metab; 2017 Jun; 19(6):909-911. PubMed ID: 28176440
    [No Abstract]   [Full Text] [Related]  

  • 57. Possible Increase in Serum FABP4 Level Despite Adiposity Reduction by Canagliflozin, an SGLT2 Inhibitor.
    Furuhashi M; Matsumoto M; Hiramitsu S; Omori A; Tanaka M; Moniwa N; Yoshida H; Ishii J; Miura T
    PLoS One; 2016; 11(4):e0154482. PubMed ID: 27124282
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Teneligliptin : expectations for its pleiotropic action.
    Morishita R; Nakagami H
    Expert Opin Pharmacother; 2015 Feb; 16(3):417-26. PubMed ID: 25597385
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prospect of Sodium-Glucose Co-transporter 2 Inhibitors Combined With Insulin for the Treatment of Type 2 Diabetes.
    Yang Y; Zhao C; Ye Y; Yu M; Qu X
    Front Endocrinol (Lausanne); 2020; 11():190. PubMed ID: 32351447
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus.
    Barnett AH; Charbonnel B; Moses RG; Kalra S
    Curr Med Res Opin; 2015; 31(10):1919-31. PubMed ID: 26361231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.